What is the weekly decitabine (Days 1, 8, 15) plus venetoclax (ramp‑up 100 mg day 1, 200 mg day 2, 400 mg day 3 then 400 mg daily) regimen for frail acute myeloid leukemia patients?

Weekly Decitabine and Venetoclax Regimen for Frail AML Patients

For frail elderly patients with AML, the weekly low-dose decitabine regimen consists of decitabine administered on Days 1,8, and 15 of each cycle, combined with venetoclax using a 3-day ramp-up (100 mg Day 1,200 mg Day 2,400 mg Day 3) followed by continuous 400 mg daily dosing. 1

Decitabine Dosing Schedule

• Decitabine is administered at 20 mg/m² intravenously on Days 1,8, and 15 of each 28-day cycle in the weekly low-dose regimen specifically designed for frail patients. 1
• This once-weekly approach differs fundamentally from the FDA-approved standard regimen of decitabine 20 mg/m² daily for 5 consecutive days every 28 days. 2
• The weekly schedule was developed specifically to reduce cytotoxic burden in elderly and frail patients who cannot tolerate severe myelosuppression. 1

Venetoclax Dosing Schedule

Initial Ramp-Up (Days 1-3)

• Day 1: Venetoclax 100 mg orally once daily 3, 1
• Day 2: Venetoclax 200 mg orally once daily 3, 1
• Day 3 onward: Venetoclax 400 mg orally once daily (target dose) 3, 1

Maintenance Dosing

• Venetoclax 400 mg continues daily throughout the entire treatment cycle without interruption after the 3-day ramp-up is completed. 1, 4
• This differs from the standard HMA/venetoclax regimen where venetoclax may be given for only 28 days per cycle. 4

Critical Safety Measures

Tumor Lysis Syndrome Prophylaxis

• All patients must receive allopurinol (or another xanthine oxidase inhibitor) beginning 2-3 days before venetoclax initiation and continuing throughout dose escalation. 3
• Inpatient hospitalization is strongly recommended throughout venetoclax dose escalation, especially during the first treatment cycle in AML patients. 3
• Aggressive hydration with oral intake of 1.5-2 L daily plus IV hydration of 150-200 mL/hour as tolerated is required. 3
• Intensive blood chemistry monitoring (potassium, uric acid, phosphorus, calcium, creatinine) should be performed pre-dose and at regular intervals during escalation. 3

Drug Interaction Management

• When strong CYP3A4 inhibitors (posaconazole, voriconazole) are required, reduce venetoclax dose by 75% to a target of 100 mg daily instead of 400 mg. 3, 5
• This 75% dose reduction applies to all escalation steps and maintenance therapy. 3

Clinical Efficacy Data

Response Rates with Weekly Regimen

• The weekly low-dose decitabine/venetoclax regimen achieved an 88% overall response rate in first-line AML patients in a retrospective cohort. 1
• For patients with TP53 mutations (typically poor prognosis), the composite complete response rate was 71% with median overall survival of 10.7 months. 1
• Patients on the weekly regimen had significantly longer time on therapy (175 days vs 78 days with standard dosing, p=0.014) and trends toward higher transfusion independence rates. 1

Standard 5-Day Decitabine/Venetoclax Comparison

• The FDA-approved standard regimen (decitabine 20 mg/m² for 5 consecutive days with venetoclax 400 mg daily) achieved 67% CR/CRi rates with median overall survival of 17.5 months. 2, 4
• CR/CRi rates vary by cytogenetic risk: 74% in intermediate-risk, 60% in poor-risk cytogenetics. 2, 6
• Molecular subgroups show differential responses: NPM1-mutated (89%), IDH1/2-mutated (71-72%), TP53-mutated (47%), FLT3-mutated (44-72%). 2, 6

Advantages of Weekly Regimen for Frail Patients

Reduced Myelosuppression

• Neutropenic fever occurred in only 31% of patients on weekly regimen, substantially lower than the 30-68% reported with standard HMA/venetoclax dosing. 1, 6
• The weekly approach allows for frequent, sustained drug exposure often not possible with standard regimens due to severe cytopenias. 1
• Patients demonstrated faster hematologic recovery and better tolerability profiles. 7

Practical Implementation

• The noncytotoxic DNA methyltransferase 1-targeting approach maintains antileukemic efficacy while mitigating myelosuppressive complications. 1
• This regimen is specifically designed for elderly and frail patients felt less likely to tolerate severe myelosuppression from standard dosing. 1

Common Pitfalls and Caveats

Do Not Accelerate Venetoclax Ramp-Up

• The 3-day venetoclax escalation schedule is mandatory and must not be shortened, even in patients with low tumor burden, to prevent tumor lysis syndrome. 3
• Never skip the allopurinol pre-treatment window; the 2-3 day lead time allows uric acid stabilization before tumor lysis begins. 3

Monitoring Requirements

• Early bone marrow assessment after completion of cycle 1 is crucial to evaluate response and guide subsequent therapy. 3
• Hold venetoclax immediately if tumor lysis syndrome develops until metabolic abnormalities resolve. 3

Alternative Standard Regimen

• If the weekly regimen is not available or appropriate, the standard FDA-approved regimen remains decitabine 20 mg/m² for 5 consecutive days every 28 days combined with venetoclax 400 mg daily (after 3-day ramp-up). 2, 4
• A 14-day venetoclax duration (rather than continuous) has shown comparable efficacy with faster neutrophil recovery in some retrospective analyses. 7